Target intelligence / Profile preview

Americium-241 ion (Am-241)

Target
Am-241
Molecular classification
Other
01

Overview

Americium-241 is a synthetic radioactive isotope and a member of the actinide series, primarily known as an alpha-particle emitter with a physical half-life of approximately 432 years [1]. It is not a natural biological component and does not serve any physiological function; instead, it is classified as a hazardous internal contaminant [1, 3]. Upon entering the human body via inhalation, ingestion, or contaminated wounds, americium-241 ions (predominantly in the trivalent state) circulate in the blood and preferentially deposit in the liver and on bone surfaces [1, 4]. The localized emission of high-energy alpha particles causes significant ionizing radiation damage to nearby cells, leading to double-strand DNA breaks and increasing the long-term risk of bone cancer (osteosarcoma), liver disease, and hematopoietic dysfunction [1, 4]. Because americium-241 is a toxicant rather than a therapeutic target, medical intervention focuses on decorporation therapy using chelating agents such as Pentetate calcium trisodium (Ca-DTPA) and Pentetate zinc trisodium (Zn-DTPA) [2]. These drugs act as chelators, sequestering the americium ions from biological ligands and facilitating their renal clearance to reduce the radiation dose to tissues [2].

Other names
241AmAmericium-241Am(III)Americium(3+)
02

Mechanism of action

Chelation of the metal ion to form a stable, water-soluble complex that is excreted in the urine.

03

Biological functions

Other
04

Disease associations

CancerOther
05

Safety considerations

Alpha radiation-induced DNA damageLong biological half-lifeBone and liver depositionNephrotoxicity of chelating agents
06

Interacting drugs

Pentetate calcium trisodium

3 more in the full profile.

07

Biomarkers

Urinary americium concentrationFecal americium concentrationWhole-body gamma countingIn vivo lung counting

Beyond the preview

Go deeper on Americium-241 ion (Am-241).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Americium-241 ion (Am-241).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call